Therefore, design of antagonists against BLT1 and 2 based on the crystal structures of BLT-ligands to block the downstream inflammatory pathways may be a promising strategy to treat obesity and its comorbidities. Here, LTB4R is linked to obesity due to melanocortin 4 receptor deficiency.